Publications by authors named "M E Cabanillas"
Background: Definitive radiotherapy (dRT) has been shown to be an effective option for patients with oligometastatic and oligoprogressive cancers; however, this approach has not been well-studied in metastatic thyroid cancer.
Methods: This retrospective cohort included 119 patients with oligometastatic (34%) and oligoprogressive (66%) metastatic thyroid cancer treated from 2005 to 2024 with 207 dRT courses for 344 sites (50% thoracic, 37% bone, 7.5% brain, 4% abdominopelvic, and 1.
Background And Purpose: Neoadjuvant BRAF-directed therapy and immunotherapy followed by surgery improves survival in patients with BRAF-mutant anaplastic thyroid carcinoma (ATC), more so in those who have complete ATC pathologic response. This study assesses the ability of FDG-PET to non-invasively detect residual high-risk pathologies including ATC and poorly differentiated thyroid carcinoma (PDTC) in the preoperative setting.
Materials And Methods: This retrospective, single-center study included consecutive BRAF-mutant ATC patients treated with at least 30 days of neoadjuvant BRAF-directed therapy and who underwent FDG-PET/CT within 30 days prior to surgery.
Article Synopsis
- This study investigates the progression patterns and outcomes of anaplastic thyroid cancer (ATC) patients with neck disease who received high-dose intensity-modulated radiation therapy (IMRT), focusing on those with unresected or partially resected tumors. !* -
- The analysis included 40 patients treated from 2010 to 2020, revealing a median overall survival of 7.1 months and a median progression-free survival of 7.4 months for those with locoregional disease. !* -
- The findings indicate that despite aggressive treatment, 53% of patients experienced loco-regional progression, predominantly in highly irradiated areas, emphasizing the need for improved targeting and strategy in treatment planning. !
Importance: Anaplastic thyroid carcinoma (ATC) is a rare and lethal cancer. Although progress has been made in recent years in patients with mutated BRAF tumors, those who respond initially eventually die of their disease; furthermore, there are no approved therapies for non-BRAF mutated tumors.
Objective: To determine whether treatment with matched-targeted therapy plus immune checkpoint inhibitors were associated with improved overall survival (OS).